Severe restriction of xenotropic murine leukemia virus-relate virus replication and spread in cultured human peripheral blood mononuclear cells

Journal of Virology

Volumn 85, Issue 10, 2011, Pages 4888-4897

  Chaipan, Chawaree ^a   Dilley, Kari A ^a   Paprotka, Tobias ^a   Delviks Frankenberry, Krista A ^a   Venkatachari, Narasimhan J ^a   Hu, Wei Shau ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GUANINE; PHYTOHEMAGGLUTININ;

AMINO ACID SUBSTITUTION; ARTICLE; CELL ACTIVATION; CELL LINE; COCULTURE; CONTROLLED STUDY; GENE MUTATION; HOST RESISTANCE; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSMISSION; XENOTROPIC MULV RELATED VIRUS;

CELLS, CULTURED; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HUMANS; LEUKOCYTES, MONONUCLEAR; VIRUS REPLICATION; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

GAMMARETROVIRUS; XENOTROPIC MURINE LEUKEMIA VIRUS;

EID: 79955438049     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00046-11     Document Type: Article

References (61)

1. Aloia, A. L., et al. 2010. XMRV: a new virus in prostate cancer? Cancer Res. 70:10028-10033.
2. Arnold, R. S., et al. 2010. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology 75:755- 761.
3. Bishop, K. N., R. K. Holmes, and M. H. Malim. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80:8450-8458.
4. Bishop, K. N., et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
5. Bogerd, H. P., F. D. B. P. Zhang, and B. R. Cullen. 2011. Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity. Virology 410:234-239.
6. Cheslock, S. R., J. A. Anderson, C. K. Hwang, V. K. Pathak, and W. S. Hu. 2000. Utilization of nonviral sequences for minus-strand DNA transfer and gene reconstitution during retroviral replication. J. Virol. 74:9571-9579.
7. Dang, Y., et al. 2008. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283:11606-11614.
8. Doehle, B. P., A. Schafer, and B. R. Cullen. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339:281-288.
9. Dong, B., et al. 2007. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. U. S. A. 104: 1655-1660.
10. Erlwein, O., et al. 2010. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One 5:e8519.
11. Fischer, N., et al. 2008. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J. Clin. Virol. 43:277-283.
12. + T lymphocytes. J. Virol. 66:6489-6495.
13. Groom, H. C, et al. 2010. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 7:10.
14. Groom, H. C., M. W. Yap, R. P. Galao, S. J. Neil, and K. N. Bishop. 2010. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl. Acad. Sci. U. S. A. 107:5166-5171.
15. Harris, R. S., et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
16. Hohn, O., et al. 2009. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology 6:92.
17. Hohn, O., et al. 2010. No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One 5:e15632.
18. Holmes, R. K., F. A. Koning, K. N. Bishop, and M. H. Malim. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595.
19. Hong, P., J. Li, and Y. Li. 2010. Failure to detect xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virol. J. 7:224.
20. Hong, S., et al. 2009. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J. Virol. 83:6995-7003.
21. Hue, S., et al. 2010. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 7:111.
22. Knouf, E. C, et al. 2009. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J. Virol. 83:7353-7356.
23. Koning, F. A., et al. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485.
24. Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
25. Lewis, P. F., and M. Emerman. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68:510-516.
26. Liddament, M. T., W. L. Brown, A. J. Schumacher, and R. S. Harris. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
27. Lochelt, M., et al. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A 102:7982-7987.
28. Lombardi, V. C, et al. 2009. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326:585-589.
29. Luo, K., et al. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81:7238-7248.
30. Mangeat, B., et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
31. Mbisa, J. L., et al. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81:7099-7110.
32. Mbisa, J. L., W. Bu, and V. K. Pathak. 2010. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84:5250-5259.
33. Mbisa, J. L., K. A. Delviks-Frankenberry, J. A. Thomas, R. J. Gorelick, and V. K. Pathak. 2009. Real-time PCR analysis of HIV-1 replication post-entry events. Methods Mol. Biol. 485:55-72.
34. Neil, S. J., T. Zang, and P. D. Bieniasz. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
35. Newman, E. N., et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
36. Oakes, B., et al. 2010. Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 7:109.
37. Paprotka, T., et al. 2010. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 84:5719-5729.
38. Refsland, E. W., et al. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
39. Robinson, M. J., et al. 2010. Mouse DNA contamination in human tissue tested for XMRV. Retrovirology 7:108.
40. Rodriguez, J. J., and S. P. Goff. 2010. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J. Virol. 84:2556-2562.
41. Roe, T., T. C. Reynolds, G. Yu, and P. O. Brown. 1993. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12:2099-2108.
42. Rose, P. P., and B. T. Korber. 2000. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 16: 400-401.
43. Sakuma, R., T. Sakuma, S. Ohmine, R. H. Silverman, and Y. Ikeda. 2010. Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology 397:1-6.
44. Sato, E., R. A. Furuta, and T. Miyazawa. 2010. An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology 7:110.
45. Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
46. Schlaberg, R., D. J. Choe, K. R. Brown, H. M. Thaker, and I. R. Singh. 2009. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl. Acad. Sci. U. S. A 106:16351-16356.
47. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
48. Shindo, K., et al. 2003. The enzymatic activity of CEM15/APOBEC-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278:44412-44416.
49. Singh, I. R., J. E. Gorzynski, D. Drobysheva, L. Bassit, and R. F. Schinazi. 2010. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 5:e9948.
50. Smith, R. A. 2010. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 7:112.
51. Smith, R. A., G. S. Gottlieb, and A. D. Miller. 2010. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 7:70.
52. Stieler, K., and N. Fischer. 2010. Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS One 5:e11738.
53. Strebel, K., T. Klimkait, and M. A. Martin. 1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-1223.
54. Stremlau, M., et al. 2004. The cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
55. Switzer, W. M., et al. 2010. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 7:57.
56. Urisman, A., et al. 2006. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2:e25.
57. Van Damme, N., et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
58. van Kuppeveld, F. J., et al. 2010. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 340:c1018.
59. Wiegand, H. L., B. P. Doehle, H. P. Bogerd, and B. R. Cullen. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458.
60. Zhang, H., et al. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
61. Zheng, Y. H., et al. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78:6073-6076.